Chest
Methods for Staging Non-small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Section snippets
General Approach
2.1.1. For patients with either a known or suspected lung cancer who are eligible for treatment, a CT scan of the chest with contrast is recommended (Grade 1B).
Remark: If PET scan is unavailable for staging, the CT of the chest should be extended to include the liver and adrenal glands to assess for metastatic disease.
2.1.2. For patients with either a known or suspected lung cancer, it is recommended that a thorough clinical evaluation be performed to provide an initial definition of tumor stage
Methods
The authors updated a systematic review of the diagnostic accuracy of different staging methods for patients with NSCLC. A more complete description of the methods can be found in the first edition of the ACCP guidelines.3, 4, 9, 10 Briefly, computerized searches of MEDLINE covering January 1991 to May 2006 for the previous guidelines and January 2006 to June 2012 for this iteration were performed. In addition, we searched the reference lists of included studies, practice guidelines, systematic
General Approach to Patients
The general approach to patients suspected of having lung cancer begins with a thorough history and physical examination. It is important to pay attention to both organ-specific (bone, brain) and nonspecific (fatigue, anorexia, weight loss) signs and symptoms of potential metastatic disease (Fig 1). The details of the clinical evaluation are discussed later, and were elucidated in detail in previous editions of the lung cancer guidelines.
Essentially, every patient suspected of having lung
Extrathoracic Staging
The work-up of patients with newly diagnosed lung cancer should begin with a thorough clinical evaluation focusing on history, physical examination, and laboratory testing germane to patients with cancer. The current preferred “expanded” clinical evaluation includes organ-specific and constitutional signs and symptoms, along with simple laboratory tests, as shown in Figure 1.36 It is well established that abnormal symptoms, physical findings, and routine blood tests in the initial clinical
General Concepts
Staging is a critical part of the evaluation of every patient with lung cancer. Defining malignant involvement of the mediastinal lymph nodes is particularly important, because in many cases, the status of these nodes determines whether there is surgically resectable disease. Clinical staging of lung cancer is usually directed by noninvasive imaging modalities. On the basis of such tests, physicians determine the likelihood of the presence or absence of tumor involvement in regional lymph nodes.
Summary
CT scanning of the chest is useful in providing anatomic detail that better identifies the location of the tumor and its proximity to local structures and determines whether lymph nodes in the mediastinum are enlarged. Unfortunately, the accuracy of chest CT scans in differentiating benign from malignant lymph nodes in the mediastinum is unacceptably low. PET scanning provides functional information of tissue activity and has much better sensitivity and specificity than chest CT scanning for
Acknowledgments
Author contributions: Dr Silvestri had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Dr Silvestri: contributed to the literature review with review of abstracts and construction of evidence tables, the interpretation of evidence tables and the formulation of recommendations, and the writing of the manuscript.
Dr Gonzalez: contributed to the literature review with review of abstracts and construction of
References (337)
- et al.
Methodology for development of guidelines for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
(2013) - et al.
Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)
Chest
(2007) - et al.
Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition)
Chest
(2007) - et al.
Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
(2013) - et al.
Multi-modality mediastinal staging for lung cancer among medicare beneficiaries
J Thorac Oncol
(2009) - et al.
Patterns of surgical care of lung cancer patients
Ann Thorac Surg
(2005) - et al.
Invasive staging of non-small cell lung cancer: a review of the current evidence
Chest
(2003) - et al.
Noninvasive staging of non-small cell lung cancer: a review of the current evidence
Chest
(2003) - et al.
Preoperative examination to detect distant metastasis is not advocated for asymptomatic patients with stages 1 and 2 non-small cell lung cancer. Preoperative examination for lung cancer
Chest
(1989) - et al.
High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy
Int J Radiat Oncol Biol Phys
(2001)
TNM staging in lung cancer: role of computed tomography
J Thorac Cardiovasc Surg
Staging of non-small cell bronchogenic carcinoma. Relationship of the clinical evaluation to organ scans
Chest
Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer
J Thorac Cardiovasc Surg
Extrathoracic staging of bronchogenic carcinoma
Chest
Detection of extrathoracic metastases by positron emission tomography in lung cancer
Ann Thorac Surg
The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival
J Thorac Cardiovasc Surg
FDG-PET in staging lung cancer: how does it change the algorithm?
Lung Cancer
The effect of FDG-PET on the stage distribution of non-small cell lung cancer
J Thorac Oncol
Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005
J Thorac Oncol
Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
Rapid disease progression with delay in treatment of non-small-cell lung cancer
Int J Radiat Oncol Biol Phys
Use of positron emission tomography in assessing hidden extrathoracic metastasis in non small cell lung cancer [in Spanish]
Arch Bronconeumol
Advances in positron emission tomography technology have increased the need for surgical staging in non-small cell lung cancer
J Thorac Cardiovasc Surg
Comparison between PET(-FDG) and computed tomography in the staging of lung cancer. Consequences for operability in 94 patients [in French]
Rev Pneumol Clin
Staging of non-small cell lung cancer. Diagnosis efficacy of structural (CT) and functional (FDG-PET) imaging methods [in Spanish]
Rev Clin Esp
Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study [in French]
Rev Pneumol Clin
The clinical impact of integrated FDG PET-CT on management decisions in patients with lung cancer
Lung Cancer
Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer
Lung Cancer
Unexpected small bowel intussusception caused by lung cancer metastasis on 18F-fluorodeoxyglucose PET-CT
Ann Thorac Surg
Factors associated with recurrence in patients with curatively resected stage I-II lung cancer
Lung Cancer
Early detection of metachronous brain metastases by biannual brain MRI follow-up may provide patients with non-small cell lung cancer with more opportunities to have radiosurgery
Clin Neurol Neurosurg
Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors
Lung Cancer
Evaluation of efficacy and clinical impact of FDG-PET on patients with potentially resectable non-small cell lung cancer [in Spanish]
Rev Esp Med Nucl
Relationship between primary tumor fluorodeoxyglucose uptake and nodal or distant metastases at presentation in T1 stage non-small cell lung cancer
Lung Cancer
Adrenal masses in lung cancer: sonographic diagnosis and follow-up
Eur J Cancer
Additional value of whole-body fluorodeoxyglucose positron emission tomography in the detection of distant metastases of non-small-cell lung cancer
Clin Lung Cancer
The value of CT scanning and percutaneous fine needle aspiration of adrenal masses in biopsy-proven lung cancer
Clin Radiol
Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases
Ann Oncol
The practice of cardiothoracic surgeons in the perioperative staging of non-small cell lung cancer
Thorax
FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy
Eur J Nucl Med Mol Imaging
Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease
Radiology
Computed tomography of the brain, chest, and abdomen in the preoperative assessment of non-small cell lung cancer
Thorax
Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning
Thorax
Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer
J Clin Oncol
Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer
J Clin Oncol
Routine positron tomography (PET) and selective mediastinoscopy is as good as routine mediastinoscopy to rule out N2 disease in non-small cell lung cancer (NSCLC)
J Clin Oncol
Preoperative staging of lung cancer with combined PET-CT
N Engl J Med
Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study
J Clin Oncol
Positron emission tomography in staging early lung cancer: a randomized trial
Ann Intern Med
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial
Lancet
Cited by (1173)
Video-assisted mediastinoscopic lymphadenectomy (VAMLA): Mature results for staging non–small cell lung cancer with normal mediastinum
2024, Journal of Thoracic and Cardiovascular SurgeryDeep learning techniques in PET/CT imaging: A comprehensive review from sinogram to image space
2024, Computer Methods and Programs in Biomedicine
Funding/Sponsors: The overall process for the development of these guidelines, including matters pertaining to funding and conflicts of interest, are described in the methodology article.1 The development of this guideline was supported primarily by the American College of Chest Physicians. The lung cancer guidelines conference was supported in part by a grant from the Lung Cancer Research Foundation. The publication and dissemination of the guidelines was supported in part by a 2009 independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
COI Grids reflecting the conflicts of interest that were current as of the date of the conference and voting are posted in the online supplementary materials.
Disclaimer: American College of Chest Physician guidelines are intended for general information only, are not medical advice, and do not replace professional medical care and physician advice, which always should be sought for any medical condition. The complete disclaimer for this guideline can be accessed at http://dx.doi.org/10.1378/chest.1435S1.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.